Previous Close | 96.88 |
Open | 96.94 |
Bid | 95.91 x 900 |
Ask | 97.52 x 900 |
Day's Range | 96.55 - 97.52 |
52 Week Range | 69.18 - 99.84 |
Volume | 2,421,367 |
Avg. Volume | 1,926,493 |
Market Cap | 218.99B |
Beta (5Y Monthly) | 0.54 |
PE Ratio (TTM) | 31.39 |
EPS (TTM) | 3.09 |
Earnings Date | N/A |
Forward Dividend & Yield | 3.09 (3.19%) |
Ex-Dividend Date | Mar. 03, 2020 |
1y Target Est | 107.00 |
Incyte's (INCY) application for pipeline candidate, retifanlimab, for adult patients with locally advanced or metastatic squamous cell carcinoma of the anal canal (SCAC) gets Priority Review.
Merck (MRK)/Bayer's (BAYRY) vericiguat gets FDA approval for symptomatic chronic heart failure and reduced ejection fraction
The Zacks Analyst Blog Highlights: Novartis, QUALCOMM, Accenture, MetLife and Electronic Arts